Olema Pharmaceuticals (OLMA) Other Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Other Accumulated Expenses data on file, last reported at $42.5 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 104.79% year-over-year to $42.5 million in Q1 2026; TTM through Mar 2026 was $42.5 million, a 104.79% increase from a year earlier, with the FY2025 full-year figure at $41.4 million, up 14.67% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $42.5 million, up from $41.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for OLMA reached as high as $42.5 million in Q1 2026 and fell as low as $53000.0 in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $17.3 million across 5 years, with a median of $17.7 million in 2023.
• Across the five-year window, Other Accumulated Expenses tumbled 98.68% in 2023 and surged 41123.61% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $15.2 million in 2022, then grew by 18.3% to $17.9 million in 2023, then surged by 101.43% to $36.1 million in 2024, then advanced by 14.67% to $41.4 million in 2025, then rose by 2.58% to $42.5 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $42.5 million in Q1 2026, $41.4 million in Q4 2025, and $29.7 million in Q3 2025.